Analyses of Factors Associated with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Review

References

• Venkatesan P. GOLD COPD report: 2023 update. Lancet Respir Med. 2023;11(1):18. doi:10.1016/S2213-2600(22)00494-5
   PubMed Web of Science ®Google Scholar
• Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi:10.7189/jogh.05.020415
   PubMed Web of Science ®Google Scholar
• Vos T, Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9
   PubMed Web of Science ®Google Scholar
• Heron M. Deaths: leading Causes for 2017. Natl Vital Stat Rep. 2019;68(6):1–77.
   PubMedGoogle Scholar
• Global. regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi:10.1016/S0140-6736(18)32279-7
   Web of Science ®Google Scholar
• Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–2242. doi:10.1016/S0140-6736(22)00470-6
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology. 2016;21(7):1152–1165. doi:10.1111/resp.12780
   PubMed Web of Science ®Google Scholar
• Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626. doi:10.1016/S2213-2600(17)30207-2
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11(1):181. doi:10.1186/1741-7015-11-181
   PubMedGoogle Scholar
• Celli BR, Fabbri LM, Aaron SD, et al. Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: best Practice. Am J Respir Crit Care Med. 2023;207(9):1134–1144. doi:10.1164/rccm.202209-1795CI
   Web of Science ®Google Scholar
• Marcos PJ, Sanjuán P, Huerta A, et al. Relationship Between Severity Classification of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Clinical Outcomes in Hospitalized Patients. Cureus. 2017;9(1):e988. doi:10.7759/cureus.988
   PubMedGoogle Scholar
• Pozo-Rodríguez F, López-Campos JL, Alvarez-Martínez CJ, et al. Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study. PLoS One. 2012;7(7):e42156. doi:10.1371/journal.pone.0042156
   PubMed Web of Science ®Google Scholar
• Escarrabill J, Torrente E, Esquinas C, et al. Clinical audit of patients hospitalized due to COPD exacerbation. MAG-1 Study. Arch Bronconeumol. 2015;51(10):483–489. doi:10.1016/j.arbres.2014.06.023
   PubMed Web of Science ®Google Scholar
• Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): a Systematic Literature Review. Int J Chron Obstruct Pulmon Dis. 2020;15:439–460. doi:10.2147/COPD.S234942
   PubMed Web of Science ®Google Scholar
• Afessa B, Morales IJ, Scanlon PD, Peters SG. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med. 2002;30(7):1610–1615. doi:10.1097/00003246-200207000-00035
   PubMed Web of Science ®Google Scholar
• Berenyi F, Steinfort DP, Abdelhamid YA, et al. Characteristics and Outcomes of Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Australia and New Zealand. Ann Am Thorac Soc. 2020;17(6):736–745. doi:10.1513/AnnalsATS.201911-821OC
   Web of Science ®Google Scholar
• Prediletto I, Giancotti G, Nava S. COPD Exacerbation: why It Is Important to Avoid ICU Admission. J Clin Med. 2023;12(10):3369. doi:10.3390/jcm12103369
   Web of Science ®Google Scholar
• Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: european COPD Audit. Eur Respir J. 2016;47(1):113–121. doi:10.1183/13993003.01391-2014
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J. 2011;37(3):508–515. doi:10.1183/09031936.00043710
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-8
   PubMed Web of Science ®Google Scholar
• Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clin Chest Med. 2020;41(3):421–438. doi:10.1016/j.ccm.2020.06.007
   PubMed Web of Science ®Google Scholar
• Ye F, He LX, Cai BQ, et al. Spectrum and antimicrobial resistance of common pathogenic bacteria isolated from patients with acute exacerbation of chronic obstructive pulmonary disease in mainland of China. Chin Med J. 2013;126(12):2207–2214.
   PubMed Web of Science ®Google Scholar
• Wark PA, Tooze M, Powell H, Parsons K. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission. Respirology. 2013;18(6):996–1002. doi:10.1111/resp.12099
   PubMed Web of Science ®Google Scholar
• Hou HH, Wang HC, Cheng SL, Chen YF, Lu KZ, Yu CJ. MMP-12 activates protease-activated receptor-1, upregulates placenta growth factor, and leads to pulmonary emphysema. Am J Physiol Lung Cell Mol Physiol. 2018;315(3):L432–L442. doi:10.1152/ajplung.00216.2017
   PubMed Web of Science ®Google Scholar
• Churg A, Zhou S, Wright JL. Series “matrix metalloproteinases in lung health and disease”: matrix metalloproteinases in COPD. Eur Respir J. 2012;39(1):197–209. doi:10.1183/09031936.00121611
   PubMed Web of Science ®Google Scholar
• Liu J, Ran Z, Wang F, Xin C, Xiong B, Song Z. Role of pulmonary microorganisms in the development of chronic obstructive pulmonary disease. Crit Rev Microbiol. 2021;47(1):1–12. doi:10.1080/1040841X.2020.1830748
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–2365. doi:10.1056/NEJMra0800353
   PubMed Web of Science ®Google Scholar
• Hurst JR, Perera WR, Wilkinson TMA, Donaldson GC, Wedzicha JA. Systemic and Upper and Lower Airway Inflammation at Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2006;173(1):71–78. doi:10.1164/rccm.200505-704OC
   PubMed Web of Science ®Google Scholar
• Sapey E. COPD exacerbations.2: aetiology. Thorax. 2006;61(3):250–258. doi:10.1136/thx.2005.041822
   PubMed Web of Science ®Google Scholar
• Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol. 2019;20(10):1279–1290. doi:10.1038/s41590-019-0451-9
   PubMed Web of Science ®Google Scholar
• Rohde G. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003;58(1):37–42. doi:10.1136/thorax.58.1.37
   PubMed Web of Science ®Google Scholar
• Choi KJ, Cha SI, Shin KM, et al. Prevalence and predictors of pulmonary embolism in Korean patients with exacerbation of chronic obstructive pulmonary disease. Respiration. 2013;85(3):203–209. doi:10.1159/000335904
   PubMed Web of Science ®Google Scholar
• Aaron SD, Angel JB, Lunau M, et al. Granulocyte Inflammatory Markers and Airway Infection during Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2001;163(2):349–355. doi:10.1164/ajrccm.163.2.2003122
   PubMed Web of Science ®Google Scholar
• Clark TW, Medina MJ, Batham S, Curran MD, Parmar S, Nicholson KG. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J. 2015;45(1):76–86. doi:10.1183/09031936.00092214
   PubMed Web of Science ®Google Scholar
• Hosseini SS, Ghasemian E, Jamaati H, Tabaraie B, Amini Z, Cox K. Association between respiratory viruses and exacerbation of COPD: a case-control study. Infect Dis. 2015;47(8):523–529. doi:10.3109/23744235.2015.1022873
   PubMed Web of Science ®Google Scholar
• Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis. 2016;10(2):158–174. doi:10.1177/1753465815618113
   PubMed Web of Science ®Google Scholar
• Stolz D, Papakonstantinou E, Grize L, et al. Time-course of upper respiratory tract viral infection and COPD exacerbation. Eur Respir J. 2019;54(4):1900407. doi:10.1183/13993003.00407-2019
   PubMed Web of Science ®Google Scholar
• Zwaans WA, Mallia P, van Winden ME, Rohde GG. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease-a systematic review. J Clin Virol. 2014;61(2):181–188. doi:10.1016/j.jcv.2014.06.025
   PubMed Web of Science ®Google Scholar
• Mohan A, Chandra S, Agarwal D, et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010;15(3):536–542. doi:10.1111/j.1440-1843.2010.01722.x
   PubMed Web of Science ®Google Scholar
• Biancardi E, Fennell M, Rawlinson W, Thomas PS. Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital. Intern Med J. 2016;46(10):1160–1165. doi:10.1111/imj.13213
   PubMed Web of Science ®Google Scholar
• Kwak HJ, Park DW, Kim JE, et al. Prevalence and Risk Factors of Respiratory Viral Infections in Exacerbations of Chronic Obstructive Pulmonary Disease. Tohoku J Exp Med. 2016;240(2):131–139. doi:10.1620/tjem.240.131
   PubMed Web of Science ®Google Scholar
• Mallia P, Message SD, Kebadze T, Parker HL, Kon OM, Johnston SL. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res. 2006;7(1). doi:10.1186/1465-9921-7-116
   Google Scholar
• Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. Eur Respir J. 2020;56(2):2002108. doi:10.1183/13993003.02108-2020
   PubMed Web of Science ®Google Scholar
• Cribbs SK, Crothers K, Morris A. Pathogenesis of HIV-Related Lung Disease: immunity, Infection, and Inflammation. Physiol Rev. 2020;100(2):603–632. doi:10.1152/physrev.00039.2018
   PubMed Web of Science ®Google Scholar
• Liu JC, Leung JM, Ngan DA, et al. Absolute leukocyte telomere length in HIV-infected and uninfected individuals: evidence of accelerated cell senescence in HIV-associated chronic obstructive pulmonary disease. PLoS One. 2015;10(4):e0124426. doi:10.1371/journal.pone.0124426
   PubMed Web of Science ®Google Scholar
• Lambert AA, Kirk GD, Astemborski J, Mehta SH, Wise RA, Drummond MB. HIV Infection Is Associated With Increased Risk for Acute Exacerbation of COPD. J Acquir Immune Defic Syndr. 2015;69(1):68–74. doi:10.1097/QAI.0000000000000552
   PubMed Web of Science ®Google Scholar
• Dimopoulos G, Lerikou M, Tsiodras S, et al. Viral epidemiology of acute exacerbations of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2012;25(1):12–18. doi:10.1016/j.pupt.2011.08.004
   PubMed Web of Science ®Google Scholar
• Choi J, Oh JY, Lee YS, et al. Bacterial and Viral Identification Rate in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Korea. Yonsei Med J. 2019;60(2):216–222. doi:10.3349/ymj.2019.60.2.216
   PubMed Web of Science ®Google Scholar
• Almansa R, Socias L, Andaluz-Ojeda D, et al. Viral infection is associated with an increased proinflammatory response in chronic obstructive pulmonary disease. Viral Immunol. 2012;25(4):249–253. doi:10.1089/vim.2011.0095
   PubMed Web of Science ®Google Scholar
• Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29(3):527–534. doi:10.1183/09031936.00092506
   PubMed Web of Science ®Google Scholar
• Hegele RG, Hayashi S, Hogg JC, Paré PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med. 1995;151(5):1659–1664. doi:10.1164/ajrccm/151.5_Pt_1.1659
   Web of Science ®Google Scholar
• George SN, Garcha DS, Mackay AJ, et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J. 2014;44(1):87–96. doi:10.1183/09031936.00223113
   PubMed Web of Science ®Google Scholar
• Mackay AJ, Kostikas K, Murray L, et al. Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations. Am J Respir Crit Care Med. 2018;198(6):730–738. doi:10.1164/rccm.201712-2482CI
   PubMed Web of Science ®Google Scholar
• Montserrat-Capdevila J, Godoy P, Marsal JR, Barbe F, Galvan L. Risk factors for exacerbation in chronic obstructive pulmonary disease: a prospective study. Int J Tuberc Lung Dis. 2016;20(3):389–395. doi:10.5588/ijtld.15.0441
   PubMed Web of Science ®Google Scholar
• Eisner M. The impact of SHS exposure on health status and exacerbations among patients with COPD. Int J Chron Obstruct Pulmon Dis. 2009;169. doi:10.2147/COPD.S4681
   Google Scholar
• Li X, Wu Z, Xue M, Du W. Smoking status affects clinical characteristics and disease course of acute exacerbation of chronic obstructive pulmonary disease: a prospectively observational study. Chron Respir Dis. 2020;17:1479973120916184. doi:10.1177/1479973120916184
   Web of Science ®Google Scholar
• Saad AB, Adhieb A, Migaou A, et al. Effect of intensity of smoking intoxication on severity parameters of acute exacerbations of chronic obstructive pulmonary disease treated in a hospital milieu. Pan Afr Med J. 2021;38:91. doi:10.11604/pamj.2021.38.91.21512
   Web of Science ®Google Scholar
• Godtfredsen NS. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax. 2002;57(11):967–972. doi:10.1136/thorax.57.11.967
   PubMed Web of Science ®Google Scholar
• Bauer CMT, Morissette MC, Stampfli MR. The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically. Chest. 2013;143(1):196–206. doi:10.1378/chest.12-0930
   PubMed Web of Science ®Google Scholar
• Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. Inflammation Res. 2008;57(11):497–503. doi:10.1007/s00011-008-8078-6
   PubMed Web of Science ®Google Scholar
• Johnston S, Molyneaux P, Singanayagam A, Joshi B, Mallia P. Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2012;555. doi:10.2147/COPD.S28286
   Web of Science ®Google Scholar
• Jin Y, Cheng Y, Wang H, Zhao C. Effects of air pollution from burning coal on respiratory diseases in adults. Wei Sheng Yan Jiu. 2001;30(4):241–243, 246.
   Google Scholar
• Schikowski T, Mills IC, Anderson HR, et al. Ambient air pollution: a cause of COPD? Eur Respir J. 2014;43(1):250–263. doi:10.1183/09031936.00100112
   PubMed Web of Science ®Google Scholar
• Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet. 2011;378(9795):991–996. doi:10.1016/S0140-6736(11)60990-2
   PubMed Web of Science ®Google Scholar
• DeVries R, Kriebel D, Sama S. Outdoor Air Pollution and COPD-Related Emergency Department Visits, Hospital Admissions, and Mortality: a Meta-Analysis. COPD. 2017;14(1):113–121. doi:10.1080/15412555.2016.1216956
   PubMedGoogle Scholar
• Li MH, Fan LC, Mao B, et al. Short-term Exposure to Ambient Fine Particulate Matter Increases Hospitalizations and Mortality in COPD: a Systematic Review and Meta-analysis. Chest. 2016;149(2):447–458. doi:10.1378/chest.15-0513
   PubMed Web of Science ®Google Scholar
• Wordley J, Walters S, Ayres JG. Short term variations in hospital admissions and mortality and particulate air pollution. Occup Environ Med. 1997;54(2):108–116. doi:10.1136/oem.54.2.108
   PubMed Web of Science ®Google Scholar
• Liu S, Zhou Y, Liu S, et al. Association between exposure to ambient particulate matter and chronic obstructive pulmonary disease: results from a cross-sectional study in China. Thorax. 2017;72(9):788–795. doi:10.1136/thoraxjnl-2016-208910
   PubMed Web of Science ®Google Scholar
• Sun XW, Chen PL, Ren L, et al. The cumulative effect of air pollutants on the acute exacerbation of COPD in Shanghai, China. Sci Total Environ. 2018;622-623:875–881. doi:10.1016/j.scitotenv.2017.12.042
   PubMed Web of Science ®Google Scholar
• Xie J, Teng J, Fan Y, Xie R, Shen A. The short-term effects of air pollutants on hospitalizations for respiratory disease in Hefei, China. Int J Biometeorol. 2019;63(3):315–326. doi:10.1007/s00484-018-01665-y
   PubMed Web of Science ®Google Scholar
• Hwang SL, Lin YC, Guo SE, Chou CT, Lin CM, Chi MC. Fine particulate matter on hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in southwestern Taiwan during 2006-2012. Int J Environ Health Res. 2017;27(2):95–105. doi:10.1080/09603123.2017.1278748
   PubMed Web of Science ®Google Scholar
• Wang W, Ying Y, Wu Q, Zhang H, Ma D, Xiao W. A GIS-based spatial correlation analysis for ambient air pollution and AECOPD hospitalizations in Jinan, China. Respir Med. 2015;109(3):372–378. doi:10.1016/j.rmed.2015.01.006
   PubMed Web of Science ®Google Scholar
• Liang L, Cai Y, Barratt B, et al. Associations between daily air quality and hospitalisations for acute exacerbation of chronic obstructive pulmonary disease in Beijing, 2013–17: an ecological analysis. Lancet Planetary Health. 2019;3(6):e270–e279. doi:10.1016/S2542-5196(19)30085-3
   PubMedGoogle Scholar
• Kelly FJ, Fussell JC. Air pollution and airway disease. Clin Exp Allergy. 2011;41(8):1059–1071. doi:10.1111/j.1365-2222.2011.03776.x
   PubMed Web of Science ®Google Scholar
• Morantes-Caballero JA, Fajardo Rodriguez HA. Effects of air pollution on acute exacerbation of chronic obstructive pulmonary disease: a descriptive retrospective study (pol-AECOPD). Int J Chron Obstruct Pulmon Dis. 2019;14:1549–1557.
   Web of Science ®Google Scholar
• Peacock JL, Anderson HR, Bremner SA, et al. Outdoor air pollution and respiratory health in patients with COPD. Thorax. 2011;66(7):591–596. doi:10.1136/thx.2010.155358
   PubMed Web of Science ®Google Scholar
• Lin MT, Kor CT, Chang CC, et al. Association of meteorological factors and air NO2 and O3 concentrations with acute exacerbation of elderly chronic obstructive pulmonary disease. Sci Rep. 2018;8(1):10192. doi:10.1038/s41598-018-28532-5
   PubMedGoogle Scholar
• Hu G, Zhou Y, Tian J, et al. Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest. 2010;138(1):20–31. doi:10.1378/chest.08-2114
   PubMed Web of Science ®Google Scholar
• Gut-Gobert C, Cavailles A, Dixmier A, et al. Women and COPD: do we need more evidence? Eur Respir Rev. 2019;28(151):180055. doi:10.1183/16000617.0055-2018
   PubMed Web of Science ®Google Scholar
• Celli BR, Halbert RJ, Nordyke RJ, Schau B. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am J Med. 2005;118(12):1364–1372. doi:10.1016/j.amjmed.2005.06.041
   PubMed Web of Science ®Google Scholar
• Salvi S, Barnes PJ. Is exposure to biomass smoke the biggest risk factor for COPD globally? Chest. 2010;138(1):3–6. doi:10.1378/chest.10-0645
   PubMed Web of Science ®Google Scholar
• Cheng LL, Liu YY, Su ZQ, Liu J, Chen RC, Ran PX. Clinical characteristics of tobacco smoke-induced versus biomass fuel-induced chronic obstructive pulmonary disease. J Transl Int Med. 2015;3(3):126–129. doi:10.1515/jtim-2015-0012
   Google Scholar
• Golpe R, Mengual-Macenlle N, Sanjuán-López P, Cano-Jiménez E, Castro-Añón O, Pérez-de-Llano LA. Prognostic Indices and Mortality Prediction in COPD Caused by Biomass Smoke Exposure. Lung. 2015;193(4):497–503.
   Web of Science ®Google Scholar
• Cho J, Lee C-H, Hwang SS, et al. Risk of acute exacerbations in chronic obstructive pulmonary disease associated with biomass smoke compared with tobacco smoke. BMC Pulm Med. 2019;19(1). doi:10.1186/s12890-019-0833-7
   Google Scholar
• Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and Chronic Obstructive Pulmonary Disease: prevalence, Influence on Outcomes, and Management. Semin Respir Crit Care Med. 2015;36(4):575–591. doi:10.1055/s-0035-1556063
   PubMed Web of Science ®Google Scholar
• Sievi NA, Senn O, Brack T, et al. Impact of comorbidities on physical activity in COPD. Respirology. 2015;20(3):413–418. doi:10.1111/resp.12456
   PubMed Web of Science ®Google Scholar
• McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62(5):411–415. doi:10.1136/thx.2006.072348
   PubMed Web of Science ®Google Scholar
• Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454–475. doi:10.1183/09059180.00008612
   PubMedGoogle Scholar
• Lin Z, Chunmei P, Xiuhong N. Predictive Value of Charlson Comorbidity Index in Prognosis of Aged Chronic Obstructive Pulmonary Disease Patients. Chine J Respir Critical Care Med. 2016;15(4):333–336.
   Google Scholar
• Almagro P, Calbo E, Ochoa de Echagüen A, et al. Mortality after hospitalization for COPD. Chest. 2002;121(5):1441–1448. doi:10.1378/chest.121.5.1441
   PubMed Web of Science ®Google Scholar
• Almagro P, Cabrera FJ, Diez J, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. Chest. 2012;142(5):1126–1133. doi:10.1378/chest.11-2413
   PubMed Web of Science ®Google Scholar
• Wong AW, Gan WQ, Burns J, Sin DD, van Eeden SF. Acute exacerbation of chronic obstructive pulmonary disease: influence of social factors in determining length of hospital stay and readmission rates. Can Respir J. 2008;15(7):361–364. doi:10.1155/2008/569496
   PubMed Web of Science ®Google Scholar
• Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respirology. 2015;20(8):1160–1171. doi:10.1111/resp.12642
   PubMed Web of Science ®Google Scholar
• Wells JM, Dransfield MT. Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:509–521. doi:10.2147/COPD.S52204
   Web of Science ®Google Scholar
• Cuttica MJ, Bhatt SP, Rosenberg SR, et al. Pulmonary artery to aorta ratio is associated with cardiac structure and functional changes in mild-to-moderate COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1439–1446. doi:10.2147/COPD.S131413
   Web of Science ®Google Scholar
• Wells JM, Morrison JB, Bhatt SP, Nath H, Dransfield MT. Pulmonary Artery Enlargement Is Associated With Cardiac Injury During Severe Exacerbations of COPD. Chest. 2016;149(5):1197–1204. doi:10.1378/chest.15-1504
   PubMed Web of Science ®Google Scholar
• Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367(10):913–921. doi:10.1056/NEJMoa1203830
   PubMed Web of Science ®Google Scholar
• Corhay JL, Vincken W, Schlesser M, Bossuyt P, Imschoot J. Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study. Int J Clin Pract. 2013;67(12):1294–1301. doi:10.1111/ijcp.12248
   PubMed Web of Science ®Google Scholar
• Ramírez E, Rodríguez A, Queiruga J, et al. Severe Hyponatremia Is Often Drug Induced: 10-Year Results of a Prospective Pharmacovigilance Program. Clin Pharmacol Ther. 2019;106(6):1362–1379. doi:10.1002/cpt.1562
   Web of Science ®Google Scholar
• Cuesta M, Slattery D, Goulden EL, et al. Hyponatraemia in patients with community-acquired pneumonia; prevalence and aetiology, and natural history of SIAD. Clin Endocrinol (Oxf). 2019;90(5):744–752. doi:10.1111/cen.13937
   Web of Science ®Google Scholar
• García-Sanz MT, Martínez-Gestoso S, Calvo-álvarez U, et al. Impact of Hyponatremia on COPD Exacerbation Prognosis. J Clin Med. 2020;9(2):503. doi:10.3390/jcm9020503
   PubMed Web of Science ®Google Scholar
• Urso C, Brucculeri S, Caimi G. Physiopathological, Epidemiological, Clinical and Therapeutic Aspects of Exercise-Associated Hyponatremia. J Clin Med. 2014;3(4):1258–1275. doi:10.3390/jcm3041258
   PubMedGoogle Scholar
• Chalela R, González-García JG, Chillarón JJ, et al. Impact of hyponatremia on mortality and morbidity in patients with COPD exacerbations. Respir Med. 2016;117:237–242. doi:10.1016/j.rmed.2016.05.003
   PubMed Web of Science ®Google Scholar
• Al Mawed S, Pankratz VS, Chong K, Sandoval M, Roumelioti ME, Unruh M. Low serum sodium levels at hospital admission: outcomes among 2.3 million hospitalized patients. PLoS One. 2018;13(3):e0194379. doi:10.1371/journal.pone.0194379
   Web of Science ®Google Scholar
• De Vecchis R, Di Maio M, Di Biase G, Ariano C. Effects of Hyponatremia Normalization on the Short-Term Mortality and Rehospitalizations in Patients with Recent Acute Decompensated Heart Failure: a Retrospective Study. J Clin Med. 2016;5(10):92. doi:10.3390/jcm5100092
   Web of Science ®Google Scholar
• Anzueto A, Miravitlles M. Pathophysiology of dyspnea in COPD. Postgrad Med. 2017;129(3):366–374. doi:10.1080/00325481.2017.1301190
   PubMed Web of Science ®Google Scholar
• Yamaya M, Usami O, Nakayama S, et al. Malnutrition, Airflow Limitation and Severe Emphysema are Risks for Exacerbation of Chronic Obstructive Pulmonary Disease in Japanese Subjects: a Retrospective Single-Center Study. Int J Chron Obstruct Pulmon Dis. 2020;15:857–868. doi:10.2147/COPD.S238457
   PubMed Web of Science ®Google Scholar
• Gulati S, Wells JM. Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: clinical and Pharmacological Considerations for Frequent Exacerbators. Drugs. 2017;77(6):651–670. doi:10.1007/s40265-017-0713-5
   Web of Science ®Google Scholar
• Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67(5):495–501. doi:10.1159/000067462
   PubMed Web of Science ®Google Scholar
• Gao J, Chen B, Wu S, Wu F. Blood cell for the differentiation of airway inflammatory phenotypes in COPD exacerbations. BMC Pulm Med. 2020;20(1):50. doi:10.1186/s12890-020-1086-1
   Web of Science ®Google Scholar
• Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967. doi:10.1016/S2213-2600(17)30432-0
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC
   PubMed Web of Science ®Google Scholar
• Brusselle G, Pavord ID, Landis S, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med. 2018;138:21–31. doi:10.1016/j.rmed.2018.03.016
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5(9):747–759. doi:10.1016/S2213-2600(17)30217-5
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442. doi:10.1016/S2213-2600(15)00106-X
   PubMed Web of Science ®Google Scholar
• Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(5):1773–1777. doi:10.1164/ajrccm.162.5.9910112
   PubMed Web of Science ®Google Scholar
• Gao P, Zhang J, He X, Hao Y, Wang K, Gibson PG. Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PLoS One. 2013;8(5):e57678. doi:10.1371/journal.pone.0057678
   PubMed Web of Science ®Google Scholar
• Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1646–1652. doi:10.1164/ajrccm.150.6.7952628
   PubMed Web of Science ®Google Scholar
• Eltboli O, Bafadhel M, Hollins F, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014;14:112. doi:10.1186/1471-2466-14-112
   PubMed Web of Science ®Google Scholar
• Abidi K, Khoudri I, Belayachi J, et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Crit Care. 2008;12(2):R59. doi:10.1186/cc6883
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016;4(9):731–741. doi:10.1016/S2213-2600(16)30148-5
   PubMed Web of Science ®Google Scholar
• Lokesh KS, Chaya SK, Jayaraj BS, et al. Vitamin D deficiency is associated with chronic obstructive pulmonary disease and exacerbation of COPD. Clin Respir J. 2021;15(4):389–399. doi:10.1111/crj.13310
   PubMed Web of Science ®Google Scholar
• Burkes RM, Ceppe AS, Doerschuk CM, et al. Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: an Analysis of the SPIROMICS Cohort. Chest. 2020;157(4):856–865. doi:10.1016/j.chest.2019.11.047
   PubMed Web of Science ®Google Scholar
• Martineau AR, James WY, Hooper RL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(2):120–130. doi:10.1016/S2213-2600(14)70255-3
   PubMed Web of Science ®Google Scholar
• Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and immune function. Nutrients. 2013;5(7):2502–2521. doi:10.3390/nu5072502
   PubMed Web of Science ®Google Scholar
• Jung JY, Kim YS, Kim SK, et al. Relationship of vitamin D status with lung function and exercise capacity in COPD. Respirology. 2015;20(5):782–789. doi:10.1111/resp.12538
   PubMed Web of Science ®Google Scholar
• Sun W, Cao Z, Ma Y, Wang J, Zhang L, Luo Z. Fibrinogen, a Promising Marker to Evaluate Severity and Prognosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a Retrospective Observational Study. Int J Chron Obstruct Pulmon Dis. 2022;17:1299–1310. doi:10.2147/COPD.S361929
   PubMed Web of Science ®Google Scholar
• Miller BE, Tal-Singer R, Rennard SI, et al. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016;193(6):607–613. doi:10.1164/rccm.201509-1722PP
   PubMed Web of Science ®Google Scholar
• Valvi D, Mannino DM, Müllerova H, Tal-Singer R. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis. 2012;7:173–182. doi:10.2147/COPD.S29892
   PubMed Web of Science ®Google Scholar
• Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic Obstr Pulm Dis. 2015;2(1):23–34. doi:10.15326/jcopdf.2.1.2014.0138
   PubMed Web of Science ®Google Scholar
• Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(10):1065–1072. doi:10.1164/rccm.201110-1792OC
   PubMed Web of Science ®Google Scholar
• Zhou B, Liu S, He D, et al. Fibrinogen is a promising biomarker for chronic obstructive pulmonary disease: evidence from a meta-analysis. Biosci Rep. 2020;40(7). doi:10.1042/BSR20193542
   Google Scholar
• Mannino DM, Valvi D, Mullerova H, Tal-Singer R. Fibrinogen, COPD and mortality in a nationally representative U.S. cohort. Copd. 2012;9(4):359–366. doi:10.3109/15412555.2012.668249
   PubMedGoogle Scholar
• Wang J, Pathak R, Garg S, Hauer-Jensen M. Fibrinogen deficiency suppresses the development of early and delayed radiation enteropathy. World J Gastroenterol. 2017;23(26):4701–4711. doi:10.3748/wjg.v23.i26.4701
   PubMed Web of Science ®Google Scholar
• Bellou V, Belbasis L, Konstantinidis AK, Evangelou E. Elucidating the risk factors for chronic obstructive pulmonary disease: an umbrella review of meta-analyses. Int J Tuberc Lung Dis. 2019;23(1):58–66. doi:10.5588/ijtld.18.0228
   Web of Science ®Google Scholar
• Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013;68(7):670–676. doi:10.1136/thoraxjnl-2012-201871
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yamamoto T, Hisatome I, et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol. 2013;375(1–2):89–96. doi:10.1016/j.mce.2013.04.027
   Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179–191. doi:10.7326/0003-4819-155-3-201108020-00008
   PubMed Web of Science ®Google Scholar
• Kahnert K, Alter P, Welte T, et al. Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respir Res. 2018;19(1):110. doi:10.1186/s12931-018-0815-y
   PubMed Web of Science ®Google Scholar
• Li H, Chen Y. Serum uric acid level as a biomarker for chronic obstructive pulmonary disease: a meta-analysis. J Int Med Res. 2021;49(1):300060520983705. doi:10.1177/0300060520983705
   PubMed Web of Science ®Google Scholar
• Kir E, Güven Atici A, Güllü YT, Köksal N, Tunçez H. The relationship between serum uric acid level and uric acid/creatinine ratio with chronic obstructive pulmonary disease severity (stable or acute exacerbation) and the development of cor pulmonale. Int J Clin Pract. 2021;75(8):e14303. doi:10.1111/ijcp.14303
   Web of Science ®Google Scholar
• Bartziokas K, Papaioannou AI, Loukides S, et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J. 2014;43(1):43–53. doi:10.1183/09031936.00209212
   PubMed Web of Science ®Google Scholar
• Horsfall LJ, Nazareth I, Petersen I. Serum uric acid and the risk of respiratory disease: a population-based cohort study. Thorax. 2014;69(11):1021–1026. doi:10.1136/thoraxjnl-2014-205271
   PubMed Web of Science ®Google Scholar
• Hogea SP, Tudorache E, Fildan AP, Fira-Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J. 2020;14(3):183–197. doi:10.1111/crj.13129
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Cardoso J, Coelho R, Rocha C, Coelho C, Semedo L, Bugalho Almeida A. Prediction of severe exacerbations and mortality in COPD: the role of exacerbation history and inspiratory capacity/total lung capacity ratio. Int J Chron Obstruct Pulmon Dis. 2018;13:1105–1113. doi:10.2147/COPD.S155848
   PubMed Web of Science ®Google Scholar
• Margüello MS, Garrastazu R, Ruiz-Nuñez M, et al. Independent effect of prior exacerbation frequency and disease severity on the risk of future exacerbations of COPD: a retrospective cohort study. NPJ Prim Care Respir Med. 2016;26:16046. doi:10.1038/npjpcrm.2016.46
   Web of Science ®Google Scholar
• Dixit D, Bridgeman MB, Andrews LB, et al. Acute exacerbations of chronic obstructive pulmonary disease: diagnosis, management, and prevention in critically ill patients. Pharmacotherapy. 2015;35(6):631–648. doi:10.1002/phar.1599
   Web of Science ®Google Scholar
• Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F, Galván L. Risk of exacerbation in chronic obstructive pulmonary disease: a primary care retrospective cohort study. BMC Fam Pract. 2015;16(1):173. doi:10.1186/s12875-015-0387-6
   Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi:10.1136/thoraxjnl-2011-201518
   PubMed Web of Science ®Google Scholar
• Osterburg AR, Lach L, Panos RJ, Borchers MT. Unique natural killer cell subpopulations are associated with exacerbation risk in chronic obstructive pulmonary disease. Sci Rep. 2020;10(1):1238. doi:10.1038/s41598-020-58326-7
   Web of Science ®Google Scholar
• Rao Y, Le Y, Xiong J, Pei Y, Sun Y. NK Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease. Front Immunol. 2021;12:666045. doi:10.3389/fimmu.2021.666045
   Web of Science ®Google Scholar
• Suzuki M, Sze MA, Campbell JD, et al. The cellular and molecular determinants of emphysematous destruction in COPD. Sci Rep. 2017;7(1):9562. doi:10.1038/s41598-017-10126-2
   PubMedGoogle Scholar
• Hodge G, Mukaro V, Holmes M, Reynolds PN, Hodge S. Enhanced cytotoxic function of natural killer and natural killer T-like cells associated with decreased CD94 (Kp43) in the chronic obstructive pulmonary disease airway. Respirology. 2013;18(2):369–376. doi:10.1111/j.1440-1843.2012.02287.x
   PubMed Web of Science ®Google Scholar
• Pascual-Guardia S, Ataya M, Ramírez-Martínez I, et al. Adaptive NKG2C+ natural killer cells are related to exacerbations and nutritional abnormalities in COPD patients. Respir Res. 2020;21(1):63. doi:10.1186/s12931-020-1323-4
   Web of Science ®Google Scholar
• Cong J, Wei H. Natural Killer Cells in the Lungs. Front Immunol. 2019;10:1416. doi:10.3389/fimmu.2019.01416
   PubMed Web of Science ®Google Scholar
• Chen YC, Lin MC, Lee CH, et al. Defective formyl peptide receptor 2/3 and annexin A1 expressions associated with M2a polarization of blood immune cells in patients with chronic obstructive pulmonary disease. J Transl Med. 2018;16(1):69. doi:10.1186/s12967-018-1435-5
   PubMedGoogle Scholar
• Leitao Filho FS, Won Ra S, Mattman A, et al. Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2017;140(4):1164–1167.e1166. doi:10.1016/j.jaci.2017.01.046
   PubMed Web of Science ®Google Scholar
• Palikhe NS, Niven M, Fuhr D, et al. Low immunoglobulin levels affect the course of COPD in hospitalized patients. Allergy Asthma Clin Immunol. 2023;19(1):10. doi:10.1186/s13223-023-00762-x
   Web of Science ®Google Scholar
• Leitao Filho FS, Mattman A, Schellenberg R, et al. Serum IgG Levels and Risk of COPD Hospitalization: a Pooled Meta-analysis. Chest. 2020;158(4):1420–1430. doi:10.1016/j.chest.2020.04.058
   PubMed Web of Science ®Google Scholar
• Jang JH, Kim JH, Park HS. Current Issues in the Management of IgG Subclass Deficiencies in Adults With Chronic Respiratory Diseases. Allergy Asthma Immunol Res. 2023;15(5):562–579. doi:10.4168/aair.2023.15.5.562
   Google Scholar
• Leitao Filho FS, Ra SW, Mattman A, et al. Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respir Res. 2018;19(1):30. doi:10.1186/s12931-018-0733-z
   PubMedGoogle Scholar
• Alotaibi NM, Filho FSL, Mattman A, et al. IgG Levels and Mortality in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021;204(3):362–365. doi:10.1164/rccm.202102-0382LE
   Web of Science ®Google Scholar
• Lee H, Kovacs C, Mattman A, et al. The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD. Respir Res. 2022;23(1):141. doi:10.1186/s12931-022-02052-3
   Web of Science ®Google Scholar
• Ragland MF, Benway CJ, Lutz SM, et al. Genetic Advances in Chronic Obstructive Pulmonary Disease. Insights from COPDGene. Am J Respir Crit Care Med. 2019;200(6):677–690. doi:10.1164/rccm.201808-1455SO
   PubMed Web of Science ®Google Scholar
• Ingebrigtsen TS, Marott JL, Vestbo J, et al. Characteristics of undertreatment in COPD in the general population. Chest. 2013;144(6):1811–1818. doi:10.1378/chest.13-0453
   PubMed Web of Science ®Google Scholar
• Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33–40. doi:10.1136/thoraxjnl-2014-205795
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi:10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Dicker AJ, Crichton ML, Cassidy AJ, et al. Genetic mannose binding lectin deficiency is associated with airway microbiota diversity and reduced exacerbation frequency in COPD. Thorax. 2018;73(6):510–518. doi:10.1136/thoraxjnl-2016-209931
   PubMed Web of Science ®Google Scholar
• Lin CL, Siu LK, Lin JC, et al. Mannose-binding lectin gene polymorphism contributes to recurrence of infective exacerbation in patients with COPD. Chest. 2011;139(1):43–51. doi:10.1378/chest.10-0375
   PubMed Web of Science ®Google Scholar
• Mandal J, Malla B, Steffensen R, et al. Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. Respir Res. 2015;16(1):150. doi:10.1186/s12931-015-0306-3
   Google Scholar
• Vogt S, Leuppi JD, Schuetz P, et al. Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial. Respir Res. 2021;22(1):227. doi:10.1186/s12931-021-01822-9
   Web of Science ®Google Scholar
• Shi W, Chen F, Cardoso WV. Mechanisms of lung development: contribution to adult lung disease and relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(7):558–563. doi:10.1513/pats.200905-031RM
   Google Scholar
• Van Durme YM, Eijgelsheim M, Joos GF, et al. Hedgehog-interacting protein is a COPD susceptibility gene: the Rotterdam Study. Eur Respir J. 2010;36(1):89–95. doi:10.1183/09031936.00129509
   Web of Science ®Google Scholar
• Pillai SG, Kong X, Edwards LD, et al. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(12):1498–1505. doi:10.1164/rccm.201002-0151OC
   PubMed Web of Science ®Google Scholar
• Vilaró J, Ramirez-Sarmiento A, Martínez-Llorens JM, et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med. 2010;104(12):1896–1902. doi:10.1016/j.rmed.2010.05.001
   PubMed Web of Science ®Google Scholar
• Gea J, Agusti A, Roca J. Pathophysiology of muscle dysfunction in COPD. J Appl Physiol. 2013;114(9):1222–1234. doi:10.1152/japplphysiol.00981.2012
   PubMed Web of Science ®Google Scholar
• Keogh E, Mark Williams E. Managing malnutrition in COPD: a review. Respir Med. 2021;176:106248. doi:10.1016/j.rmed.2020.106248
   PubMed Web of Science ®Google Scholar
• Martinez CH, Diaz AA, Meldrum CA, et al. Handgrip Strength in Chronic Obstructive Pulmonary Disease. Associations with Acute Exacerbations and Body Composition. Ann Am Thorac Soc. 2017;14(11):1638–1645. doi:10.1513/AnnalsATS.201610-821OC
   PubMed Web of Science ®Google Scholar
• Liang Y, Sun YC. Nutrition management of patients with acute exacerbation of chronic obstructive pulmonary disease hospitalized in Respiratory Intensive Care Unit. Zhonghua Jie He He Hu Xi Za Zhi. 2022;45(9):920–925. doi:10.3760/cma.j.cn112147-20220422-00342
   Google Scholar
• Marco E, Sánchez-Rodríguez D, Dávalos-Yerovi VN, et al. Malnutrition according to ESPEN consensus predicts hospitalizations and long-term mortality in rehabilitation patients with stable chronic obstructive pulmonary disease. Clin Nutr. 2019;38(5):2180–2186. doi:10.1016/j.clnu.2018.09.014
   PubMed Web of Science ®Google Scholar
• Limpawattana P, Putraveephong S, Inthasuwan P, Boonsawat W, Theerakulpisut D, Chindaprasirt J. Frailty syndrome in ambulatory patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1193–1198. doi:10.2147/COPD.S134233
   PubMed Web of Science ®Google Scholar
• Ter Beek L, van der Vaart H, Wempe JB, et al. Coexistence of malnutrition, frailty, physical frailty and disability in patients with COPD starting a pulmonary rehabilitation program. Clin Nutr. 2020;39(8):2557–2563. doi:10.1016/j.clnu.2019.11.016
   PubMed Web of Science ®Google Scholar
• Jingrong LI. Analysis of the prevalence and influencing factors of chronic obstructive pulmonary disease in elderly hospitalized patients: a study based on a Comprehensive Geriatric Assessment System in Yunnan Province. Chinese General Practice. 2022;25(11):1320–1326.
   Google Scholar
• Tramontano A, Palange P. Nutritional State and COPD: effects on Dyspnoea and Exercise Tolerance. Nutrients. 2023;15(7):1786. doi:10.3390/nu15071786
   Web of Science ®Google Scholar
• Yohannes AM, Mülerová H, Lavoie K, et al. The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. J Am Med Dir Assoc. 2017;18(11):955–959.e956. doi:10.1016/j.jamda.2017.05.024
   PubMed Web of Science ®Google Scholar
• Atlantis E, Fahey P, Cochrane B, Smith S. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest. 2013;144(3):766–777. doi:10.1378/chest.12-1911
   PubMed Web of Science ®Google Scholar
• Holas P, Michalowski J, Gaweda L, Domagala-Kulawik J. Agoraphobic avoidance predicts emotional distress and increased physical concerns in chronic obstructive pulmonary disease. Respir Med. 2017;128:7–12. doi:10.1016/j.rmed.2017.04.011
   Web of Science ®Google Scholar
• T-P N. Depressive Symptoms and Chronic Obstructive Pulmonary Disease. Arch Intern Med. 2007;167(1):60. doi:10.1001/archinte.167.1.60
   Google Scholar
• Huang J, Bian Y, Zhao Y, Jin Z, Liu L, Li G. The Impact of Depression and Anxiety on Chronic Obstructive Pulmonary Disease Acute Exacerbations: a prospective cohort study. J Affect Disord. 2021;281:147–152. doi:10.1016/j.jad.2020.12.030
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38–45. doi:10.1183/09031936.00194610
   PubMed Web of Science ®Google Scholar
• Almagro P, Hernandez C, Martinez-Cambor P, Tresserras R, Escarrabill J. Seasonality, ambient temperatures and hospitalizations for acute exacerbation of COPD: a population-based study in a metropolitan area. Int J Chron Obstruct Pulmon Dis. 2015;10:899–908. doi:10.2147/COPD.S75710
   PubMed Web of Science ®Google Scholar
• Li X, Wu Z, Xue M, Du W. An observational study of the effects of smoking cessation earlier on the clinical characteristics and course of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2022;22(1):390. doi:10.1186/s12890-022-02187-5
   Web of Science ®Google Scholar
• Hosking L, Yeo A, Hoffman J, et al. Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation. Respir Med. 2021;187:106573. doi:10.1016/j.rmed.2021.106573
   PubMed Web of Science ®Google Scholar